Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Veridex, Llc
Journal of Clinical Oncology Article Highlights CellSearch Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer
August 5th, 2008
An international, prospective clinical trial found the number of circulating tumor cells (CTCs) is a strong indicator of progression-free and overall survival among metastatic colorectal cancer patients, according to a report published in the July 1 issue of the Journal of Clinical Oncology. The study, conducted in the US, the Netherlands, and the United Kingdom, found that metastatic colorectal cancer patients with fewer than three circulating tumor cells in their bloodstream had significantly better overall survival than patients with more than three CTCs. "Given the variety of cancer drugs available today, the ability to monitor CTCs in...
Source: Cancer Weekly (2008-08-05)
|
